Stem Cell Therapeutics Announces Share Consolidation Proposal

Stem Cell Therapeutics Announces Share Consolidation Proposal 
TORONTO, ONTARIO -- (Marketwire) -- 11/26/12 -- Stem Cell
Therapeutics Corp. (TSX VENTURE:SSS), announces today that consistent
with the Company's corporate objective of the acquisition and
development of additional stem cell-based therapies, and in order to
attract the capital required to support this objective, management
and the board of directors recommend the consolidation of the
outstanding shares. 
Consolidation will permit the issuance of additional securities not
currently permitted under $0.10 per share that has limited the
Company's options. The consolidation is generally expected to be
advantageous to the Company's corporate objectives and in attracting
investors to the opportunities that may emerge from the Company's
rebuilding. A meeting of shareholders will be held on December 20th,
2012 to vote on the recommendation of the board to consolidate the
outstanding common shares on the basis of a ratio to be proposed by
the board of directors in the range of one post-consolidation common
share for each 10 to 30 outstanding pre-consolidation common shares.  
The meeting will be held at the Offices of McCarthy Tetrault LLP,
Toronto Dominion Bank Tower, 53rd Floor, J.J. Robinette Boardroom, TD
Centre, 66 Wellington Street West, Toronto, ON M5K 1E6, on December
20, 2012, at 10:00 am (Toronto time). Shareholders will receive the
Information Circular and proxy form shortly. Shareholders may vote by
phoning in their election, or by internet or mail, and are also
invited to attend the meeting should they wish. Questions related to
this proposal may be emailed to David Allan, Executive Chairman. 
The board of directors recommends the consolidation as being in the
Company's interest and an important step in meeting the objectives
for the repositioning of the Company. 
About Stem Cell Therapeutics: 
Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) is a Canadian
commercialization receptor company in the business of developing stem
cell-based therapeutics through partnerships with research
institutions or technology transfer organizations. The Company's
corporate objectives include the analysis and acquisition of
additional stem cell-related development opportunities and securing
capital for the advanc
ement of the licensed or acquired products. In
October 2012 SCT became a member of the 20-member Centre for
Commercialization of Regenerative Medicine ("CCRM") consortium. SCT
has extensive expertise and experience in the stem cell biotechnology
sector based on the intellectual property of Dr. Samuel Weiss in stem
cell research. SCT proposes to build upon the foundational
technologies by acquiring additional early-stage clinical or
late-stage preclinical candidates. SCT's Traumatic Brain Injury
product, NTx(R)-428, is currently in a Phase II clinical trial. For
more information, visit: 
Caution Regarding Forward-Looking Information:  
Certain statements contained in this press release constitute
forward-looking information within the meaning of applicable Canadian
provincial securities legislation (collectively, the "forward-looking
statements"). These forward-looking statements relate to, among other
things, SCT's objectives, goals, targets, strategies, intentions,
plans, beliefs, estimates and outlook, and can, in some cases, be
identified by the use of words such as "believe," "anticipate,"
"expect," "intend," "plan," "will," "may" and other similar
expressions. In addition, any statements that refer to expectations,
projections or other characterizations of future events or
circumstances are forward-looking statements. These statements
reflect management's current beliefs and are based on information
currently available to management. Certain material factors or
assumptions are applied in making forward-looking statements, and
actual results may differ materially from those expressed or implied
in such statements. Important factors that could cause actual results
to differ materially from these expectations include, among other
things: uncertainties and risks related to, the availability of
capital, changes in capital markets, uncertainties related to
clinical trials and product development, rapid technological change,
uncertainties related to forecasts, competition, potential product
liability, unproven markets for technologies in development, the cost
and supply of raw materials, management of growth, effects of
payers'' willingness to pay for products, risks related to regulatory
matters and risks related to intellectual property matters.
Additional information about these factors and about the material
factors or assumptions underlying such forward-looking statements may
be found in the body of this news release, as well as under the
heading "Risk Factors" contained in SCT's 2010 annual information
form. SCT cautions that the foregoing list of important factors that
may affect future results is not exhaustive.  
When relying on SCT's forward-looking statements to make decisions
with respect to SCT, investors and others should carefully consider
the foregoing factors and other uncertainties and potential events.
Such forward-looking statements are based on a number of estimates
and assumptions which may prove to be incorrect, including, but not
limited to, assumptions regarding the availability of financing for
research and development companies in addition to general business
and economic conditions. These risks and uncertainties should be
considered carefully and investors and others should not place undue
reliance on the forward-looking statements. Although the
forward-looking statements contained in this press release are based
upon what management believes to be reasonable assumptions, SCT
cannot provide assurance that actual results will be consistent with
these forward-looking statements. SCT undertakes no obligation to
update or revise any forward-looking statement.  
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release. 
Stem Cell Therapeutics Corp.
David Allan
Executive Chairman
Press spacebar to pause and continue. Press esc to stop.